<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141164">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01818583</url>
  </required_header>
  <id_info>
    <org_study_id>AK-01</org_study_id>
    <nct_id>NCT01818583</nct_id>
  </id_info>
  <brief_title>Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diakonhjemmet Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diakonhjemmet Hospital</source>
  <oversight_info>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation is a condition in which the heart's upper chambers, the atria, contract
      at an abnormally rapid rate. It is a common type of arrhythmia, and occurs in 1-2% of the
      general population. The prevalence of atrial fibrillation increases with age. Between 50 and
      70% of patients with atrial fibrillation lasting &lt;48 hours spontaneously convert to normal
      sinus rhythm, and drug therapy increases the likelihood of conversion to sinus rhythm.
      Another treatment option for conversion of atrial fibrillation and atrial flutter is
      electrical conversion. This is an effective treatment but requires anesthesia.

      Current treatment strategy for medical conversion of atrial fibrillation and atrial flutter
      is to employ drugs that affect ion channel activity in atrial cardiomyocytes. However, such
      converting drugs all have potentially serious side effects and are expensive. Potassium,
      sodium, calcium, and magnesium molecules are the most important ions causing electric
      current in the heart tissue. Our hypothesis is that hypokalemia promotes atrial
      fibrillation/atrial flutter by a direct effect on cardiomyocytes. Accordingly, we also
      hypothesize that potassium infusion may convert atrial fibrillation/atrial flutter to normal
      sinus rhythm. If so, this would be an inexpensive treatment with potentially very few side
      effects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cardioversion (time and percentage)</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation at 3 months follow up visit and during 72 hours ECG-monitoring period.</measure>
    <time_frame>At 3 months follow up, plus additional 3 days ECG-monitoring</time_frame>
    <safety_issue>No</safety_issue>
    <description>The patients will be followed up with a resting ECG three months after study intervention, and subsequently on-demand ECG will be monitored for 72 hours.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>During time of infusion</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <condition>Potassium</condition>
  <condition>Cardioversion</condition>
  <arm_group>
    <arm_group_label>Potassium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Potassium chloride infusion at a rate of 10 mmol/h (80 mmol KCl in 1000 ml of 5% glucose with a concentration of 0.08 mmol/mL, flow rate 125 mL/h). If the serum Mg ≤0.8 mmol/L, MgSO4 infusion (0.5 mmol/kg/24 hours in 1000 mL NaCl 0.9% corresponding to an infusion rate of approximately 42 mL/hour) will also be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5% glucose (flow rate 125 ml/h) as placebo infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium chloride</intervention_name>
    <arm_group_label>Potassium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with paroxysmal atrial fibrillation/atrial flutter with duration &lt;48 hours
             or &lt;7 days and who are anticoagulated and have had INR &gt;2 in &gt;3 weeks

          -  Serum potassium ≤4,0 mmol/L.

          -  Age ≥ 18 år

        Exclusion Criteria:

          -  Potassium &gt; 4,0 mmol/L

          -  eGFR &lt;30 mL/min

          -  Patients on antiarrhythmic therapy (flecainid, amiodarone, dronedarone or    sotalol)

          -  Pregnancy

          -  Breast feeding

          -  Patients participating in a clinical trial during the last six months

          -  Addison disease, adynamia episodic hereditary, or Sickle cell anemia

          -  Metabolic acidosis, pH &lt; 7,2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Øie, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Diakonhjemmet Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erik Øie, MD, PhD</last_name>
    <phone>+47-22454055</phone>
    <email>erik.oie@diakonsyk.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kiarash Tazmini, MD</last_name>
    <phone>+47-22451500</phone>
    <email>kiarash.tazmini@diakonsyk.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diakonhjemmet Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0370</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Øie, MD, PhD</last_name>
      <phone>+47-22454055</phone>
      <email>erik.oie@diakonsyk.no</email>
    </contact>
    <contact_backup>
      <last_name>Kiarash Tazmini, MD</last_name>
      <phone>+47-22451500</phone>
      <email>kiarash.tazmini@diakonsyk.no</email>
    </contact_backup>
    <investigator>
      <last_name>Kiarash Tazmini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 22, 2013</lastchanged_date>
  <firstreceived_date>March 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diakonhjemmet Hospital</investigator_affiliation>
    <investigator_full_name>Kiarash Tazmini</investigator_full_name>
    <investigator_title>Kiarash Tazmini,  MD</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Atrial flutter</keyword>
  <keyword>Potassium</keyword>
  <keyword>Cardioversion</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
